Beta-Glucans for High Cholesterol (Dyslipidemia)

The honest headline: beta-glucan from oats and barley reliably nudges LDL cholesterol down, by roughly 10 mg/dL on average (0.25 mmol/L × 38.7). Meta-analyses of 13 to 58 randomised trials found reductions of 0.19 to 0.27 mmol/L, and the US Food and Drug Administration allows a heart-disease health claim for 3 g or more a day from whole oats or barley.

Two things temper that. The effect is small compared with a statin, and the best-designed tablet trial found no LDL change at all. Think of beta-glucan as a food-based add-on to the usual plan for high cholesterol, not a stand-in for medication. For the broader picture of what this fibre does, see the beta-glucans page; the same fibre's effect on the lipid outcome is covered under cholesterol management.

Oat and barley beta-glucan is a viscous soluble fibre. Its best-supported action is on bile acids. In a controlled crossover study of 30 adults with mild hypercholesterolaemia, 3 g/day of high molecular weight barley beta-glucan lowered total cholesterol and increased bile acid synthesis (P=0.049), while cholesterol absorption (P=0.25) and cholesterol synthesis (P=0.14) did not change significantly.

The authors concluded that increased bile acid synthesis, rather than reduced cholesterol absorption or synthesis, may be responsible for the cholesterol-lowering effect.

In the same 30-person design, 3 g/day of high molecular weight beta-glucan lowered total cholesterol by 0.12 mmol/L versus control, but low molecular weight beta-glucan at 3 or 5 g/day did not. The response was larger in carriers of a G allele of the CYP7A1 gene variant rs3808607. A separate three-week crossover in 14 healthy young adults found no difference from control for oat, barley or barley mutant beta-glucan.

What the mechanism cannot tell you: these were small studies, the genotype finding is exploratory, and nothing here shows that a particular supplement product has the right viscosity. That gap is one plausible reason food-based and tablet results disagree.

The US rule behind the health claim specifies 3 g or more per day of beta-glucan soluble fibre from whole oats or barley, or a combination. The largest oat meta-analysis pooled trials giving at least 3 g/day (range 3.0 to 12.4 g/day over 2 to 12 weeks) and found no evidence that dose or duration changed the result. The barley meta-analysis used a median 6.5 g/day for a median 4 weeks.

Read labels for grams of beta-glucan, not grams of oats. The tablet trial tested 1.5, 3 and 6 g/day and none of the doses lowered LDL, so the dose on a supplement label does not ensure the effect seen with oat or barley foods.

Oat beta-glucan: a 2014 meta-analysis of 28 trials found that 3 g/day or more reduced LDL cholesterol by 0.25 mmol/L (95% CI 0.20 to 0.30; P<0.0001) and total cholesterol by 0.30 mmol/L, with no effect on HDL cholesterol or triglycerides. A 2016 analysis of 58 trials (n=3,974) found a smaller 0.19 mmol/L LDL reduction at a median 3.5 g/day, with considerable heterogeneity (I2=79%). A 2022 analysis of 13 trials in 927 people with high cholesterol found LDL down by 0.27 mmol/L and total cholesterol down by 0.24 mmol/L.

Barley beta-glucan: 14 trials (n=615) at a median 6.5 g/day for a median 4 weeks lowered LDL cholesterol by 0.25 mmol/L (95% CI 0.20 to 0.30) and non-HDL cholesterol by 0.31 mmol/L, but apoB did not change significantly. The 2014 oat analysis also found greater LDL lowering at higher baseline LDL.

A 2024 meta-analysis of 17 trials (n=1,731) in people with dyslipidaemia found an LDL reduction of 0.24 mmol/L from oat-based products (moderate certainty), but most trials were at high risk of bias or had some concerns, and the products included oat bran and whole grain oats as well as beta-glucan. One study found no significant difference in major cardiovascular events.

The clearest negative result is a 2023 randomised, double-blind trial in 263 adults with LDL above 3.37 mmol/L. A beta-glucan tablet at 1.5, 3 or 6 g/day for 12 weeks did not change LDL compared with placebo (P=0.23, 0.18 and 0.72), and total cholesterol, non-HDL cholesterol, apoB and hs-CRP were also unchanged. A smaller crossover in 14 healthy young adults likewise found no difference from control, although oat beta-glucan lowered LDL against baseline.

No trial reviewed here followed people long enough to show fewer heart attacks or strokes from beta-glucan itself. The head-to-head question, beta-glucan against a statin or against other fibres such as psyllium husk, is also not answered by these studies. Results vary widely between trials, and the trial populations and food forms differ.

Gastrointestinal effects were the main adverse events: the 2024 meta-analysis reported diarrhoea, nausea and flatulence as the most frequent with oat products. In the tablet trial, gastrointestinal events were reported by 23.4%, 34.8% and 66.7% of the 1.5, 3 and 6 g groups against 36.9% on placebo. The overall comparison across the four groups was significant (P<0.0001), with the highest rate in the 6 g group.

The studies reviewed do not address pregnancy, breastfeeding or use in children, so those groups should ask a clinician before using extracts or concentrates. Keep eating oats and barley as foods if you tolerate them.

The trials reviewed did not report drug interactions with oat or barley beta-glucan. The tablet trial enrolled people treated or not with a statin and did not single out an interaction in its abstract, but absence of a report is not proof of safety, so tell your prescriber and pharmacist what you add.